NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,414.78 +207.65 (+1.14%) CRUDE OIL
79.20 +0.25 (+0.32%) GOLD FUTURES
2,316.30 +6.70 (+0.29%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,444.80 +1,659.50 (+3.62%)
Legend Biotech Corporation (LEGN)
After hours:
| Previous close | 43.98 |
| Open | 44.50 |
| Bid | 45.89 x 200 |
| Ask | 45.98 x 100 |
| Day's range | 43.65 - 45.97 |
| 52-week range | 42.08 - 77.32 |
| Volume | |
| Avg. volume | 1,000,681 |
| Market cap | 8.355B |
| Beta (5Y monthly) | 0.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
SOMERSET, N.J., April 22, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the European Commission (EC) has granted approval of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), have demonstrated disease progression on
- Business Wire
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
SOMERSET, N.J., April 11, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.
- Business Wire
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
SOMERSET, N.J., April 06, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), and are refractory to lenalidomide.1 CARVYKTI®
